{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T07:47:10Z","timestamp":1772524030039,"version":"3.50.1"},"reference-count":106,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Delta-Fly Pharma, Inc"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2020]]},"DOI":"10.1016\/j.addr.2020.08.002","type":"journal-article","created":{"date-parts":[[2020,8,8]],"date-time":"2020-08-08T11:06:00Z","timestamp":1596884760000},"page":"27-36","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["An RNAi therapeutic, DFP-10825, for intraperitoneal and intrapleural malignant cancers"],"prefix":"10.1016","volume":"154-155","author":[{"given":"Hidenori","family":"Ando","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuhiro","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2020.08.002_bb0005","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0092-8674(00)80620-0","article-title":"RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals","volume":"101","author":"Zamore","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.addr.2020.08.002_bb0010","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/35078107","article-title":"Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells","volume":"411","author":"Elbashir","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.addr.2020.08.002_bb0015","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/nature04688","article-title":"RNAi-mediated gene silencing in non-human primates","volume":"441","author":"Zimmermann","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.addr.2020.08.002_bb0020","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/nm1486","article-title":"In vivo imaging of siRNA delivery and silencing in tumors","volume":"13","author":"Medarova","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2020.08.002_bb0025","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.addr.2009.04.006","article-title":"Nonviral vector-mediated RNA interference: its gene silencing characteristics and important factors to achieve RNAi-based gene therapy","volume":"61","author":"Takahashi","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2020.08.002_bb0030","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/35888","article-title":"Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans","volume":"391","author":"Fire","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.addr.2020.08.002_bb0035","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2020.08.002_bb0040","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/j.ymthe.2017.03.013","article-title":"Lipid nanoparticle systems for enabling gene therapies","volume":"25","author":"Cullis","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.addr.2020.08.002_bb0045","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1042\/CS20130497","article-title":"Cytokine networking of innate immunity cells: a potential target of therapy","volume":"126","author":"Striz","year":"2014","journal-title":"Clin. Sci. (Lond.)"},{"key":"10.1016\/j.addr.2020.08.002_bb0050","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2010-08-265892","article-title":"Cytokine release from innate immune cells: association with diverse membrane trafficking pathways","volume":"118","author":"Lacy","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.addr.2020.08.002_bb0055","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jconrel.2017.11.043","article-title":"Complement activation in vitro and reactogenicity of low-molecular weight dextran-coated SPIONs in the pig CARPA model: correlation with physicochemical features and clinical information","volume":"270","author":"Fulop","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2020.08.002_bb0060","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.molimm.2014.06.038","article-title":"Complement activation-related pseudoallergy: a stress reaction in blood triggered by nanomedicines and biologicals","volume":"61","author":"Szebeni","year":"2014","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.addr.2020.08.002_bb0065","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.tox.2005.07.023","article-title":"Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity","volume":"216","author":"Szebeni","year":"2005","journal-title":"Toxicology"},{"key":"10.1016\/j.addr.2020.08.002_bb0070","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.nano.2015.12.377","article-title":"Comparison of complement activation-related pseudoallergy in miniature and domestic pigs: foundation of a validatable immune toxicity model","volume":"12","author":"Jackman","year":"2016","journal-title":"Nanomedicine"},{"key":"10.1016\/j.addr.2020.08.002_bb0075","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v18.i6.50","article-title":"Complement activation-related pseudoallergy caused by liposomes, micellar carriers of intravenous drugs, and radiocontrast agents","volume":"18","author":"Szebeni","year":"2001","journal-title":"Crit. Rev. Ther. Drug Carrier Syst."},{"key":"10.1016\/j.addr.2020.08.002_bb0080","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.addr.2007.03.005","article-title":"RNAi therapeutics: principles, prospects and challenges","volume":"59","author":"Aagaard","year":"2007","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2020.08.002_bb0085","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jconrel.2014.07.056","article-title":"Current issues of RNAi therapeutics delivery and development","volume":"195","author":"Haussecker","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2020.08.002_bb0090","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jconrel.2014.04.044","article-title":"Development of RNAi technology for targeted therapy--a track of siRNA based agents to RNAi therapeutics","volume":"193","author":"Zhou","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2020.08.002_bb0095","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-017-0683-y","article-title":"Nano-based delivery of RNAi in cancer therapy","volume":"16","author":"Xin","year":"2017","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.addr.2020.08.002_bb0100","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2147\/JBM.S159297","article-title":"An investigational RNAi therapeutic targeting antithrombin for the treatment of hemophilia a and B","volume":"9","author":"Machin","year":"2018","journal-title":"J. Blood Med."},{"key":"10.1016\/j.addr.2020.08.002_bb0105","doi-asserted-by":"crossref","first-page":"7313","DOI":"10.1002\/cam4.2598","article-title":"A novel intraperitoneal therapy for gastric cancer with DFP-10825, a unique RNAi therapeutic targeting thymidylate synthase, in a peritoneally disseminated xenograft model","volume":"8","author":"Ando","year":"2019","journal-title":"Cancer Med."},{"key":"10.1016\/j.addr.2020.08.002_bb0110","doi-asserted-by":"crossref","first-page":"673","DOI":"10.2147\/DDDT.S156635","article-title":"Anticancer activity of the intraperitoneal-delivered DFP-10825, the cationic liposome-conjugated RNAi molecule targeting thymidylate synthase, on peritoneal disseminated ovarian cancer xenograft model","volume":"12","author":"Iizuka","year":"2018","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.addr.2020.08.002_bb0115","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.3892\/ijo.2016.3367","article-title":"Downregulation of thymidylate synthase by RNAi molecules enhances the antitumor effect of pemetrexed in an orthotopic malignant mesothelioma xenograft mouse model","volume":"48","author":"Abu Lila","year":"2016","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.addr.2020.08.002_bb0120","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1200\/JCO.2003.02.043","article-title":"Pemetrexed and cisplatin for malignant pleural mesothelioma: a new standard of care?","volume":"21","author":"Rusch","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.addr.2020.08.002_bb0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10120-016-0622-4","article-title":"Gastric Cancer, Japanese gastric cancer treatment guidelines 2014 (ver. 4)","volume":"20","author":"Japanese","year":"2017","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.addr.2020.08.002_bb0130","doi-asserted-by":"crossref","first-page":"6047","DOI":"10.1073\/pnas.092143499","article-title":"RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells","volume":"99","author":"Yu","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2020.08.002_bb0135","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/nbt0502-497","article-title":"U6 promoter-driven siRNAs with four uridine 3\u2032 overhangs efficiently suppress targeted gene expression in mammalian cells","volume":"20","author":"Miyagishi","year":"2002","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.addr.2020.08.002_bb0140","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.tcb.2005.03.006","article-title":"RNA silencing and genome regulation","volume":"15","author":"Almeida","year":"2005","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.addr.2020.08.002_bb0145","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.cell.2004.06.017","article-title":"Single processing center models for human dicer and bacterial RNase III","volume":"118","author":"Zhang","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.addr.2020.08.002_bb0150","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.molcel.2004.07.007","article-title":"Human Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs","volume":"15","author":"Meister","year":"2004","journal-title":"Mol. Cell"},{"key":"10.1016\/j.addr.2020.08.002_bb0155","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1126\/science.1102513","article-title":"Argonaute2 is the catalytic engine of mammalian RNAi","volume":"305","author":"Liu","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.addr.2020.08.002_bb0160","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1089\/oli.2006.0069","article-title":"shRNAs targeting hepatitis C: effects of sequence and structural features, and comparision with siRNA","volume":"17","author":"Vlassov","year":"2007","journal-title":"Oligonucleotides"},{"key":"10.1016\/j.addr.2020.08.002_bb0165","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1002\/jps.20968","article-title":"Potency of siRNA versus shRNA mediated knockdown in vivo","volume":"96","author":"McAnuff","year":"2007","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2020.08.002_bb0170","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nbt1052","article-title":"Synthetic shRNAs as potent RNAi triggers","volume":"23","author":"Siolas","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.addr.2020.08.002_bb0175","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.addr.2016.01.022","article-title":"The role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide delivery","volume":"99","author":"Cheng","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2020.08.002_bb0180","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1007\/s11095-006-9180-5","article-title":"Lipid-based nanoparticles for nucleic acid delivery","volume":"24","author":"Li","year":"2007","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2020.08.002_bb0185","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3389\/fimmu.2017.00331","article-title":"RNA interference-induced innate immunity, off-target effect, or immune adjuvant?","volume":"8","author":"Meng","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.addr.2020.08.002_bb0190","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1038\/nbt1161","article-title":"Activation of the mammalian immune system by siRNAs","volume":"23","author":"Marques","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.addr.2020.08.002_bb0195","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1261\/rna.5103703","article-title":"siRNA function in RNAi: a chemical modification analysis","volume":"9","author":"Chiu","year":"2003","journal-title":"Rna"},{"key":"10.1016\/j.addr.2020.08.002_bb0200","doi-asserted-by":"crossref","first-page":"7295","DOI":"10.1021\/jo2012225","article-title":"Chemical modification of siRNA bases to probe and enhance RNA interference","volume":"76","author":"Peacock","year":"2011","journal-title":"J. Organomet. Chem."},{"key":"10.1016\/j.addr.2020.08.002_bb0205","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1089\/hum.2015.070","article-title":"Oligonucleotide therapies: the past and the present","volume":"26","author":"Lundin","year":"2015","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.addr.2020.08.002_bb0210","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25071725","article-title":"A unique gene-silencing approach, using an intelligent RNA expression device (iRed), results in minimal immune stimulation when given by local intrapleural injection in malignant pleural mesothelioma","volume":"25","author":"Ando","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.addr.2020.08.002_bb0215","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2015.48","article-title":"Gene silencing using 4'-thioDNA as an artificial template to synthesize short hairpin RNA without inducing a detectable innate immune response","volume":"5","author":"Tarashima","year":"2016","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.addr.2020.08.002_bb0220","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.cell.2016.06.028","article-title":"Emt: 2016","volume":"166","author":"Nieto","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.addr.2020.08.002_bb0225","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-16066-2","article-title":"Context specificity of the EMT transcriptional response","volume":"11","author":"Cook","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2020.08.002_bb0230","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrm1835","article-title":"Complex networks orchestrate epithelial-mesenchymal transitions","volume":"7","author":"Thiery","year":"2006","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.addr.2020.08.002_bb0235","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/35000034","article-title":"The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells","volume":"2","author":"Batlle","year":"2000","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.addr.2020.08.002_bb0240","doi-asserted-by":"crossref","first-page":"5075","DOI":"10.1038\/onc.2008.140","article-title":"Snail promotes Wnt target gene expression and interacts with beta-catenin","volume":"27","author":"Stemmer","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.addr.2020.08.002_bb0245","doi-asserted-by":"crossref","first-page":"11740","DOI":"10.1074\/jbc.M413878200","article-title":"Wnt-dependent regulation of the E-cadherin repressor snail","volume":"280","author":"Yook","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2020.08.002_bb0250","doi-asserted-by":"crossref","first-page":"952","DOI":"10.3892\/etm.2012.511","article-title":"Intratumoral Wnt2B expression affects tumor proliferation and survival in malignant pleural mesothelioma patients","volume":"3","author":"Kobayashi","year":"2012","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.addr.2020.08.002_bb0255","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.athoracsur.2013.01.012","article-title":"Snail expression is associated with a poor prognosis in malignant pleural mesotheliomas","volume":"95","author":"Kobayashi","year":"2013","journal-title":"Ann. Thorac. Surg."},{"key":"10.1016\/j.addr.2020.08.002_bb0260","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/j.ejca.2011.05.003","article-title":"Adenoviral vector expressing short hairpin RNA targeting Wnt2B has an effective antitumour activity against Wnt2B2-overexpressing tumours","volume":"48","author":"Liu","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.addr.2020.08.002_bb0265","doi-asserted-by":"crossref","first-page":"5887","DOI":"10.21873\/anticanres.11175","article-title":"Ad-shWnt2b vector therapy demonstrates antitumor activity in orthotopic intrapleural models as monitored with the in vitro imaging system (IVIS)","volume":"36","author":"Kobayashi","year":"2016","journal-title":"Anticancer Res."},{"key":"10.1016\/j.addr.2020.08.002_bb0270","first-page":"2455","article-title":"Thymidylate synthetase (TS) genotype and TS\/dihydropyrimidine dehydrogenase mRNA level as an indicator in determining chemosensitivity to 5-fluorouracil in advanced gastric carcinoma","volume":"24","author":"Toriumi","year":"2004","journal-title":"Anticancer Res."},{"key":"10.1016\/j.addr.2020.08.002_bb0275","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1007\/s10120-014-0413-8","article-title":"Impact of the expression of thymidylate synthase and dihydropyrimidine dehydrogenase genes on survival in stage II\/III gastric cancer","volume":"18","author":"Sasako","year":"2015","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.addr.2020.08.002_bb0280","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1002\/cncr.21777","article-title":"Significance of thymidylate synthase gene expression level in patients with adenocarcinoma of the lung, Cancer-am","volume":"106","author":"Hashimoto","year":"2006","journal-title":"Cancer Soc."},{"key":"10.1016\/j.addr.2020.08.002_bb0285","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/path.4897","article-title":"Thymidylate synthase is functionally associated with ZEB1 and contributes to the epithelial-to-mesenchymal transition of cancer cells","volume":"242","author":"Siddiqui","year":"2017","journal-title":"J. Pathol."},{"key":"10.1016\/j.addr.2020.08.002_bb0290","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1038\/s41418-019-0289-6","article-title":"Thymidylate synthase maintains the de-differentiated state of triple negative breast cancers","volume":"26","author":"Siddiqui","year":"2019","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.addr.2020.08.002_bb0295","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ijpharm.2014.12.047","article-title":"Solid lipid nanoparticles as non-viral vector for the treatment of chronic hepatitis C by RNA interference","volume":"479","author":"Torrecilla","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2020.08.002_bb0300","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1080\/02648725.2016.1178011","article-title":"Towards effective non-viral gene delivery vector","volume":"31","author":"Simcikova","year":"2015","journal-title":"Biotechnol. Genet. Eng. Rev."},{"key":"10.1016\/j.addr.2020.08.002_bb0305","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2174\/18722113113079990010","article-title":"Cationic liposomes as non-viral vector for RNA delivery in cancer immunotherapy","volume":"7","author":"Vitor","year":"2013","journal-title":"Recent Pat. Drug Deliv. Formul."},{"key":"10.1016\/j.addr.2020.08.002_bb0310","doi-asserted-by":"crossref","first-page":"8529","DOI":"10.1002\/anie.201203263","article-title":"Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo","volume":"51","author":"Jayaraman","year":"2012","journal-title":"Angew. Chem. Int. Ed. Eng."},{"key":"10.1016\/j.addr.2020.08.002_bb0315","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/978-1-4939-9092-4_22","article-title":"Anti-PEG IgM production via a PEGylated nanocarrier system for nucleic acid delivery","volume":"1943","author":"Abu Lila","year":"2019","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.addr.2020.08.002_bb0320","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.imbio.2015.06.005","article-title":"Anti-PEG IgM and complement system are required for the association of second doses of PEGylated liposomes with splenic marginal zone B cells","volume":"220","author":"Shimizu","year":"2015","journal-title":"Immunobiology"},{"key":"10.1016\/j.addr.2020.08.002_bb0325","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/978-1-62703-140-0_4","article-title":"Anti-PEG IgM production via a PEGylated nano-carrier system for nucleic acid delivery","volume":"948","author":"Ichihara","year":"2013","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.addr.2020.08.002_bb0330","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jconrel.2013.07.026","article-title":"The accelerated blood clearance (ABC) phenomenon: clinical challenge and approaches to manage","volume":"172","author":"Abu Lila","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2020.08.002_bb0335","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jconrel.2007.02.010","article-title":"Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes","volume":"119","author":"Wang","year":"2007","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2020.08.002_bb0340","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jconrel.2006.08.017","article-title":"Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin-encapsulation and high-dose first injection","volume":"115","author":"Ishida","year":"2006","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2020.08.002_bb0345","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.ijpharm.2019.04.054","article-title":"A simplified method for manufacturing RNAi therapeutics for local administration","volume":"564","author":"Ando","year":"2019","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2020.08.002_bb0350","first-page":"358","article-title":"Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study","volume":"88","author":"Sadeghi","year":"2000","journal-title":"Cancer-Am. Cancer Soc."},{"key":"10.1016\/j.addr.2020.08.002_bb0355","first-page":"1485","article-title":"Clinicopathological features of long-term survivors of scirrhous gastric cancer","volume":"47","author":"Takahashi","year":"2000","journal-title":"Hepatogastroenterology"},{"key":"10.1016\/j.addr.2020.08.002_bb0360","doi-asserted-by":"crossref","first-page":"167","DOI":"10.5230\/jgc.2011.11.3.167","article-title":"Clinical outcomes according to primary treatment in gastric cancer patients with peritoneal seeding","volume":"11","author":"Bae","year":"2011","journal-title":"J. Gastric Cancer"},{"key":"10.1016\/j.addr.2020.08.002_bb0365","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/978-1-4613-1247-5_4","article-title":"Peritoneal-plasma barrier","volume":"82","author":"Jacquet","year":"1996","journal-title":"Cancer Treat. Res."},{"key":"10.1016\/j.addr.2020.08.002_bb0370","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s10120-003-0226-7","article-title":"Experimental study to evaluate the usefulness of S-1 in a model of peritoneal dissemination of gastric cancer","volume":"6","author":"Mori","year":"2003","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.addr.2020.08.002_bb0375","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.soc.2012.07.002","article-title":"Current status and future directions in gastric cancer with peritoneal dissemination","volume":"21","author":"Glockzin","year":"2012","journal-title":"Surg. Oncol. Clin. N. Am."},{"key":"10.1016\/j.addr.2020.08.002_bb0380","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/s10120-016-0660-y","article-title":"Intraperitoneal chemotherapy for gastric cancer with peritoneal disease: experience from Singapore and Japan","volume":"20","author":"Kono","year":"2017","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.addr.2020.08.002_bb0385","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s10120-016-0662-9","article-title":"Intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis","volume":"20","author":"Kobayashi","year":"2017","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.addr.2020.08.002_bb0390","article-title":"Hyperthermic intraperitoneal chemotherapy in ovarian cancer","volume":"10","author":"Riggs","year":"2020","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.addr.2020.08.002_bb0395","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ejca.2019.10.034","article-title":"Indications for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery: a systematic review","volume":"127","author":"Auer","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.addr.2020.08.002_bb0400","doi-asserted-by":"crossref","first-page":"55657","DOI":"10.18632\/oncotarget.17497","article-title":"Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival for peritoneal carcinomatosis from colorectal cancer: a systematic review and meta-analysis of current evidence","volume":"8","author":"Huang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.addr.2020.08.002_bb0405","doi-asserted-by":"crossref","first-page":"5926","DOI":"10.1177\/0300060519882545","article-title":"Effect of hyperthermic intraperitoneal chemotherapy for gastric cancer patients: a meta-analysis of the randomized controlled trials","volume":"47","author":"Liu","year":"2019","journal-title":"J. Int. Med. Res."},{"key":"10.1016\/j.addr.2020.08.002_bb0410","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1158\/1078-0432.CCR-12-0261","article-title":"Phase I trial of intraperitoneal pemetrexed, cisplatin, and paclitaxel in optimally debulked ovarian cancer","volume":"18","author":"Chambers","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.addr.2020.08.002_bb0415","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.sbi.2017.05.010","article-title":"Structural insights into ligand recognition and regulation of nucleic acid-sensing toll-like receptors","volume":"47","author":"Shimizu","year":"2017","journal-title":"Curr. Opin. Struct. Biol."},{"key":"10.1016\/j.addr.2020.08.002_bb0420","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/imr.12375","article-title":"Nucleic acid-sensing TLRs and autoimmunity: novel insights from structural and cell biology","volume":"269","author":"Pelka","year":"2016","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.addr.2020.08.002_bb0425","doi-asserted-by":"crossref","first-page":"4845","DOI":"10.1158\/1078-0432.CCR-15-0866","article-title":"siRNA lipid nanoparticle potently silences clusterin and delays progression when combined with androgen receptor cotargeting in enzalutamide-resistant prostate cancer","volume":"21","author":"Yamamoto","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.addr.2020.08.002_bb0430","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nbt.1602","article-title":"Rational design of cationic lipids for siRNA delivery","volume":"28","author":"Semple","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.addr.2020.08.002_bb0435","doi-asserted-by":"crossref","first-page":"16958","DOI":"10.1021\/ja505986a","article-title":"Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing","volume":"136","author":"Nair","year":"2014","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.addr.2020.08.002_bb0440","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0046091","article-title":"Early detection of malignant pleural mesothelioma in asbestos-exposed individuals with a noninvasive proteomics-based surveillance tool","volume":"7","author":"Ostroff","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2020.08.002_bb0445","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1038\/bjc.2011.400","article-title":"Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin","volume":"105","author":"Giovannetti","year":"2011","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.addr.2020.08.002_bb0450","doi-asserted-by":"crossref","first-page":"158","DOI":"10.5694\/j.1326-5377.2009.tb02321.x","article-title":"Early detection of malignant pleural mesothelioma through measurement of soluble mesothelin-related protein and positron emission tomography","volume":"190","author":"O'Lone","year":"2009","journal-title":"Med. J. Aust."},{"key":"10.1016\/j.addr.2020.08.002_bb0455","first-page":"262","article-title":"Localized malignant mesothelioma of the pleura","volume":"13","author":"Takahashi","year":"2007","journal-title":"Ann. Thorac. Cardiovasc. Surg."},{"key":"10.1016\/j.addr.2020.08.002_bb0460","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2486\/indhealth.42.435","article-title":"Malignant pleural mesothelioma in parts of Japan in relationship to asbestos exposure","volume":"42","author":"Kishimoto","year":"2004","journal-title":"Ind. Health"},{"key":"10.1016\/j.addr.2020.08.002_bb0465","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/sj.bjc.6602307","article-title":"The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050","volume":"92","author":"Hodgson","year":"2005","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.addr.2020.08.002_bb0470","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1179\/oeh.2003.9.3.249","article-title":"Asbestos-related morbidity in India","volume":"9","author":"Joshi","year":"2003","journal-title":"Int. J. Occup. Environ. Health"},{"key":"10.1016\/j.addr.2020.08.002_bb0475","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/JTO.0b013e318031d05c","article-title":"Four-modality therapy in malignant pleural mesothelioma: a phase II study","volume":"2","author":"Lucchi","year":"2007","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.addr.2020.08.002_bb0480","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3816\/CLC.2010.n.005","article-title":"Carboplatin plus pemetrexed as first-line treatment of patients with malignant pleural mesothelioma: a phase II study","volume":"11","author":"Katirtzoglou","year":"2010","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.addr.2020.08.002_bb0485","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3892\/ol.2013.1688","article-title":"Significance of thymidylate synthase expression for resistance to pemetrexed in pulmonary adenocarcinoma","volume":"7","author":"Yang","year":"2014","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.addr.2020.08.002_bb0490","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.canlet.2011.06.006","article-title":"Establishment of pemetrexed-resistant non-small cell lung cancer cell lines","volume":"309","author":"Zhang","year":"2011","journal-title":"Cancer Lett."},{"key":"10.1016\/j.addr.2020.08.002_bb0495","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1349-7006.2009.01358.x","article-title":"Significance of thymidylate synthase for resistance to pemetrexed in lung cancer","volume":"101","author":"Ozasa","year":"2010","journal-title":"Cancer Sci."},{"key":"10.1016\/j.addr.2020.08.002_bb0500","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0939-6411(98)00004-6","article-title":"Freeze-drying of bioproducts: putting principles into practice","volume":"45","author":"Franks","year":"1998","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2020.08.002_bb0505","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1023\/B:PHAM.0000016234.73023.75","article-title":"Design of freeze-drying processes for pharmaceuticals: practical advice","volume":"21","author":"Tang","year":"2004","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2020.08.002_bb0510","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0076-6879(03)67008-4","article-title":"Freeze-drying of liposomes: theory and practice","volume":"367","author":"van Winden","year":"2003","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.addr.2020.08.002_bb0515","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jconrel.2003.10.021","article-title":"Stabilization of oligonucleotide-polyethylenimine complexes by freeze-drying: physicochemical and biological characterization","volume":"95","author":"Brus","year":"2004","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2020.08.002_bb0520","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.ejpb.2008.04.026","article-title":"Formulation development of freeze-dried oligonucleotide-loaded gelatin nanoparticles","volume":"70","author":"Zillies","year":"2008","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2020.08.002_bb0525","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1002\/jps.10108","article-title":"Evidence of lipoplex dissociation in liquid formulations","volume":"91","author":"Lai","year":"2002","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2020.08.002_bb0530","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/(SICI)1520-6017(200003)89:3<355::AID-JPS7>3.0.CO;2-H","article-title":"Lyophilization of cationic lipid-protamine-DNA (LPD) complexes","volume":"89","author":"Li","year":"2000","journal-title":"J. Pharm. Sci."}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X20301137?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X20301137?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T04:48:33Z","timestamp":1759207713000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X20301137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":106,"alternative-id":["S0169409X20301137"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2020.08.002","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An RNAi therapeutic, DFP-10825, for intraperitoneal and intrapleural malignant cancers","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2020.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}